Abacavir/3TC once daily pill gets scientific approval as Kivexa in Europe

This article is more than 15 years old. Click here for more recent articles on this topic

GlaxoSmithKline’s once daily fixed dose combination of abacavir and 3TC (lamivudine) has received scientific approval from the European Medicines Agency, it was announced on Friday.

The product is already licensed in the United States as Epzicom but will be prescribed under the trade name Kivexa in Europe.

Kivexa is likely to receive marketing approval from the European Commission within three to four months and will then be available for prescription in the European Union. In the United Kingdom Kivexa is already available on a named patient basis if doctors think that a once daily fixed dose combination of abacavir and 3TC may promote better adherence to treatment for an individual patient.